Insomnia, anxiety and depression Mental and Behavioural Disorders Nonorganic insomnia, Anxiety disorder, unspecified, Depressive episode, unspecified
Conditions
Interventions
Participants are randomly allocated through blocked randomisation with stratification into the SLEEP intervention or a waitlist control group with a 1:1 allocation ratio. The researchers will stratify
Sponsors
University of Warwick
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. Able to give informed consent 2. English-speaking 3. In employment (including being on furlough) 4. Insomnia Severity Index score: x >8 5. General Anxiety Disorder-7 score: x >5 or Patient Health Questionnaire-9 score: x >5 6. =18 years of age
Exclusion criteria
Exclusion criteria: 1. Currently receiving treatment (psychological or pharmacological) from mental health services (e.g. GP, Improving Access to Psychological Therapies (IAPT), specialist and community mental health services) 2. Not pregnant 3. Current substance abuse/misuse problems, epilepsy, neurological conditions (e.g. Parkinson’s or Alzheimer’s), psychosis, bipolar disorder, or any other circadian rhythm and sleep disorders (e.g. sleep apnoea, periodic limb movement syndrome/restless leg syndrome, circadian rhythm disorders) 4. Retiring in the next 10 months 5. Currently taking part in other psychological intervention trials 6. In shift work
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Insomnia measured using the Insomnia Severity Index at baseline, post-intervention (8 weeks) and follow-up (12 weeks) 2. Anxiety measured using the General Anxiety Disorder-7 at baseline, post-intervention (8 weeks) and follow-up (12 weeks) 3. Depression measured using the Patient Health Questionnaire-9 at baseline, post-intervention (8 weeks) and follow-up (12 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 26/10/2021: 1. Sleep quality parameters measured using Camntech MotionWatch actigraphy trackers and self-reported sleep diary data at week 1 (pre-intervention) and week 8 (post-intervention) 2. Work productivity measured using the Work Productivity and Activity Impairment: General Health v2.0 at baseline, post-intervention (8 weeks) and follow up (12 weeks) 3. Job satisfaction measured using the Indiana Job Satisfaction Scale at baseline, post-intervention (8 weeks) and follow up (12 weeks) 4. Well-being measured using the Warwick-Edinburgh Mental Health Well-being Scale at baseline, post-intervention (8 weeks) and follow up (12 weeks) 5. Quality of life measured using the EuroQOL EQ-5D-5L questionnaire at baseline, post-intervention (8 weeks) and follow up (12 weeks) 6. User experience behaviour of platform usage collected as the counts of activities completed on the platform as well as the average duration of time spent on each topic over the 8-week intervention period. _____ Previous secondary outcome measures: 1. Sleep quality parameters measured using Camntech MotionWatch actigraphy trackers at week 1 (pre-intervention) and week 8 (post-intervention) 2. Job productivity measured using the Work Productivity and Activity Impairment: General Health v2.0 at baseline, post-intervention (8 weeks) and follow up (12 weeks) 3. Job satisfaction measured using the Indiana Job Satisfaction Scale at baseline, post-intervention (8 weeks) and follow up (12 weeks) 4. Well-being measured using the Warwick-Edinburgh Mental Health Well-being Scale at baseline, post-intervention (8 weeks) and follow up (12 weeks) 5. Quality of life measured using the EuroQOL EQ-5D-5L questionnaire at baseline, post-intervention (8 weeks) and follow up (12 weeks) 6. User experience behaviour of platform usage collected as the number of log-ins and counts of activities completed on the platform over the 8-week intervention period. These will be downloade | — |
Countries
England, United Kingdom
Contacts
Public ContactCharlotte Kershaw
Outcome results
None listed